JTE 151

Drug Profile

JTE 151

Alternative Names: JTE-151

Latest Information Update: 08 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orphagen Pharmaceuticals
  • Developer Japan Tobacco
  • Class Antiallergics
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Hypersensitivity

Most Recent Events

  • 01 Jun 2018 Orphagen Pharmaceuticals has patent protection for small molecule ligands to inhibit retinoid-related orphan receptor gamma in USA
  • 02 May 2016 Discontinued - Phase-I for Autoimmune disorders (PO)
  • 02 May 2016 Discontinued - Phase-I for Hypersensitivity (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top